[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"strongyloidiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:strongyloidiasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100641330","phase-3-combination-therapies-for-trichuris-trichiura-infection-in-schoolchildren-in-honduras-100641330",false,"NCT07661316","Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras","Randomized, Open-Label, Assessor-Blinded Clinical Trial of Combination Therapies Versus Standard Treatment for Trichuris Trichiura Infection in Schoolchildren in La Moskitia, Honduras","AIM-T","Inclusion Criteria:\n\n* Trichuris trichiura infection documented by quantitative real-time PCR (qPCR) performed within 30 days prior to randomization.\n* Age 6 to 15 years inclusive.\n* Written informed consent provided by a parent or legal guardian. Assent provided by children aged 9 years or older, according to local ethical requirements.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to albendazole or ivermectin.\n* Receipt of an anthelmintic treatment (albendazole, mebendazole, or ivermectin) within 3 months prior to enrollment.\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Severe comorbidity at the investigator's discretion (e.g., diarrhea, tuberculosis, or malaria).\n* Body weight \\\u003C15 kg.\n* Positive pregnancy test or refusal to undergo pregnancy testing in post-menarcheal girls and female adolescents of childbearing potential.","ALL","6 Years","15 Years",{"count":21,"type":22},368,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this Phase III clinical trial is to evaluate the efficacy, safety, and acceptability of different treatment regimens for Trichuris trichiura infection in schoolchildren aged 6 to 15 years living in La Moskitia, Honduras, an area with a high burden of soil-transmitted helminth infections.\n\nThe main questions it aims to answer are:\n\n* Are combination treatments of albendazole and ivermectin more effective than albendazole alone for treating Trichuris trichiura infection?\n* Does a fixed-dose combination (FDC) of albendazole and ivermectin achieve cure rates comparable to co-administration of the two drugs?\n* How effective are the different treatment regimens against other soil-transmitted helminths, including Strongyloides stercoralis?\n* What adverse events occur following treatment with the different regimens?\n* How acceptable are the different treatment regimens to children and their caregivers?\n\nResearchers will compare four treatment groups: placebo, albendazole alone, albendazole plus ivermectin, and a fixed-dose combination of albendazole plus ivermectin.\n\nParticipants will:\n\n* Be randomly assigned to one of the four treatment groups.\n* Receive a single dose of the assigned treatment.\n* Provide stool samples before treatment and approximately 21 days after treatment.\n* Undergo laboratory testing using quantitative real-time PCR (qPCR) to detect and quantify helminth infections.\n* Be monitored for adverse events after treatment.\n* Complete acceptability assessments together with their caregivers.\n\nThe study will provide evidence on the efficacy, safety, and acceptability of a fixed-dose combination of albendazole and ivermectin and its potential use as a simplified treatment strategy for the control of soil-transmitted helminth infections in endemic settings.",[28,29,30,31,32],"Trichuriasis","Strongyloidiasis","Ascariasis","Hookworm Infection","Soil-Transmitted Helminthiasis",[34,35,36,37,38,39,40],"HONDURAS","TRICHURIS TRICHIURA","IVERMECTIN","MOSKITIA","SCHOOL AGE CHILDREN","SOIL TRANSMITTED HELMINTHIASIS","ALBENDAZOLE AND IVERMECTIN FIXED DOSE COMBINATION","NOT_YET_RECRUITING","2026-06-18",{"date":44,"type":45},"2026-06-23","ACTUAL",{"date":47,"type":22},"2026-11-01",{"date":49,"type":22},"2027-05-31",{"name":51,"class":52},"Mundo Sano Foundation","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":53},"100605196","phase-3-better-options-for-lymphatic-filariasis-treatment-100605196","NCT07159373","Better Options for Lymphatic Filariasis Treatment","Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji","BOLT","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent.\n2. Resident in one of the study locations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria to participation in the study.\n\nTreatment Exclusion Criteria:\n\nParticipants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria:\n\n1. Severe illness (any illness that is severe enough to interfere with activities of daily living);\n2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole;\n3. Pregnant;\n4. Breastfeeding a baby within 7 days of birth;\n5. Age \\\u003C 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or\n6. Age \\\u003C 2 years or weight \\\u003C 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).",true,{"count":64,"type":22},5100,[25],"The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:\n\n1. Does MoxDA clear infection in people with lymphatic filariasis ?\n2. Does MoxDA cause any medical problems in infected and uninfected people?\n\nResearchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems.\n\nParticipants will:\n\n1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis\n2. Take 3 single doses of MoxDA or IDA, 12 months apart\n3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups",[68,69,29],"Lymphatic Filariasis","Scabies",[71,72,73,74,69,29,75,76,77],"Moxidectin","Ivermectin","Mass drug administration","Lymphatic filariasis","Cluster-randomized","Diethylcarbamazine","Albendazole","2025-09-03",{"date":80,"type":45},"2025-09-08",{"date":82,"type":22},"2026-03",{"date":84,"type":22},"2028-06",{"name":86,"class":52},"Medicines Development for Global Health"]